PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMoxetumomab pasudotox
Lumoxiti(moxetumomab pasudotox)
Lumoxiti (moxetumomab pasudotox) is an antibody drug conjugate pharmaceutical. Moxetumomab pasudotox was first approved as Lumoxiti on 2018-09-13. It is used to treat hairy cell leukemia in the USA. It has been approved in Europe to treat hairy cell leukemia. The pharmaceutical is active against B-cell receptor CD22.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Moxetumomab pasudotox
Tradename
Proper name
Company
Number
Date
Products
Lumoxitimoxetumomab pasudotox-tdfkAstraZenecaN-761104 DISCN2018-09-13
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
iv stabilizer lumoxitiBiologic Licensing Application2020-09-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hairy cell leukemia—D007943C91.4
Agency Specific
FDA
EMA
Expiration
Code
moxetumomab pasudotox, Lumoxiti, Innate Pharma, Inc.
2025-09-13Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FB: Cd22 (clusters of differentiation 22) inhibitors
— L01FB02: Moxetumomab pasudotox
HCPCS
Code
Description
J9313
Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Clinical
Clinical Trials
18 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hairy cell leukemiaD007943—C91.4————22
LeukemiaD007938—C95————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMoxetumomab pasudotox
INNmoxetumomab pasudotox
Description
Moxetumomab pasudotox (mouse mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1743043
ChEBI ID—
PubChem CID—
DrugBankDB12688
UNII ID2NDX4B6N8F (ChemIDplus, GSRS)
Target
Agency Approved
CD22
CD22
Organism
Homo sapiens
Gene name
CD22
Gene synonyms
SIGLEC2
NCBI Gene ID
933
Protein name
B-cell receptor CD22
Protein synonyms
B-lymphocyte cell adhesion molecule, BL-CAM, CD22, CD22 antigen, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
Uniprot ID
P20273
Mouse ortholog
Cd22 (12483)
B-cell receptor CD22 (Q9WU51)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 829 documents
View more details
Safety
Black-box Warning
Black-box warning for: Iv stabilizer lumoxiti
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
69 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use